Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.

Trial Profile

Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Epirubicin (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 22 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top